Ferring Pharmaceuticals received authorization from the European Commission to market Firmagon, a prostate cancer drug. The treatment is a gonadotropin-releasing hormone receptor antagonist, indicated for patients with advanced, hormone-dependent prostate cancer. It is supplied as a powder to be reconstituted with sterile water for subcutaneous administration in the abdomen.
The authorization follows degarelix' FDA approval in December 2008.
In Phase III trials, Firmagnon reportedly reduced the levels of testosterone in more than 96% of patients within three days. Results were close to the immediate effect achieved with surgery, explains Ferring.